Top 10 Companies in the (R)-2-Bromobutanoic acid (CAS 2033-94-9) Market (2026): Market Leaders Driving Global Chemical Innovation

MARKET INSIGHTS

Global (R)-2-Bromobutanoic acid (CAS 2681-94-9) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

(R)-2-Bromobutanoic acid (CAS 2033-94-9) Market – View in Detailed Research Report

(R)-2-Bromobutanoic acid (CAS 2681-94-9) is a chiral alpha‑bromocarboxylic acid with the molecular formula C“H”BrO“, recognized for its high enantiomeric purity and reactivity as a synthetic building block. The compound plays a critical role in asymmetric synthesis, particularly in the production of chiral pharmaceuticals, agrochemicals, and fine chemical intermediates. Its (R)-configuration makes it especially valuable in stereoselective chemical reactions where precise molecular geometry is essential to biological activity.

The market is witnessing steady growth driven by the expanding demand for enantiopure compounds in pharmaceutical manufacturing, where regulatory agencies increasingly require chiral purity in active pharmaceutical ingredients (APIs). Furthermore, the rising adoption of green chemistry practices and advances in asymmetric catalysis are broadening the compound’s application scope. Key suppliers operating in this space include Thermo Fisher Scientific, TCI Chemicals, and Sigma‑Aldrich (Merck KGaA), among other specialty chemical manufacturers with dedicated chiral compound portfolios.

---

Top 10 Companies in the (R)-2-Bromobutanoic acid (CAS 2033-94-9) Market (2026)

1️⃣ Ningbo Inno Pharmchem Co., Ltd. (China)

Headquarters: Ningbo, China
Key Offering: High‑purity (R)-2‑Bromobutanoic acid for pharmaceutical intermediates

Ningbo Inno Pharmchem has developed a proprietary kinetic resolution platform that delivers enantiomeric excesses above 99.5% while maintaining yields above 80%. The company’s integrated downstream purification reduces waste and shortens lead times, positioning it as a preferred partner for contract manufacturers seeking rapid scale‑up.

Sustainability Initiatives:

• Implementation of solvent‑free resolution processes to cut CO₂ footprint by 35%
• Adoption of renewable energy sources for 50% of production capacity
• Partnerships with local universities to refine biocatalytic routes

2️⃣ Clearsynth (India)

Headquarters: Bengaluru, India
Key Offering: Custom chiral synthesis services and bulk supply of (R)-2‑Bromobutanoic acid

Clearsynth’s modular synthesis platform allows clients to tailor reaction conditions, enabling cost‑effective production of high‑purity intermediates for both pharma and agrochemical sectors. Its FDA‑inspected facilities give it an edge in markets demanding stringent regulatory compliance.

Sustainability Initiatives:

• Zero‑waste policy in all active sites
• Investment in water recycling technologies reducing consumption by 40%
• Collaboration with NGOs to promote green chemistry education

3️⃣ Finetech Industry Limited (China)

Headquarters: Shanghai, China
Key Offering: Technical‑grade (R)-2‑Bromobutanoic acid for fine chemical synthesis

Finetech’s focus on process intensification has enabled the company to deliver high‑yield, low‑cost chiral intermediates to a growing portfolio of chemical manufacturers. Its continuous‑flow systems reduce energy usage and accelerate production cycles.

Sustainability Initiatives:

• Integration of heat‑recovery units lowering energy consumption by 20%
• Use of biodegradable solvents in downstream purification
• Employee training programs on green chemistry best practices

4️⃣ Biosynth (Switzerland)

Headquarters: Zurich, Switzerland
Key Offering: Ultra‑high‑purity (R)-2‑Bromobutanoic acid for API development

Biosynth’s GMP‑compliant facilities provide the industry with enantiomeric excesses exceeding 99.9%. The company’s investment in enzymatic resolution technology has shortened synthesis routes, reducing both cost and environmental impact.

Sustainability Initiatives:

• Biocatalytic processes that cut solvent use by 60%
• Renewable energy sourcing for 70% of production energy
• Transparent reporting of life‑cycle emissions

5️⃣ Enamine Ltd. (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: Custom synthesis of (R)-2‑Bromobutanoic acid for research and development

Enamine’s flexible contract‑manufacturing model accommodates a range of purity specifications, from technical to pharmaceutical grade. Despite regional challenges, the company has maintained uninterrupted supply chains through strategic partnerships with global distributors.

Sustainability Initiatives:

• Use of green catalysts reducing hazardous waste
• Investment in local renewable energy projects
• Support for open‑source green chemistry research

6️⃣ Pharmaffiliates Analytics & Synthetics (India)

Headquarters: Pune, India
Key Offering: High‑purity (R)-2‑Bromobutanoic acid for API intermediates

Pharmaffiliates’ focus on rapid prototyping and regulatory support enables it to meet tight development timelines for emerging therapeutic candidates. The company’s scalable production lines accommodate both small‑batch and large‑scale demands.

Sustainability Initiatives:

• Adoption of green solvents in all purification steps
• Carbon‑neutral manufacturing targets by 2030
• Community outreach on sustainable chemical manufacturing

7️⃣ Apollo Scientific Ltd. (UK)

Headquarters: London, United Kingdom
Key Offering: Pharmaceutical‑grade (R)-2‑Bromobutanoic acid for advanced drug discovery

Apollo Scientific’s strict quality controls and rapid turnaround times make it a go‑to partner for European pharma firms. Its investment in analytical instrumentation ensures traceability of enantiomeric purity throughout the supply chain.

Sustainability Initiatives:

• Zero‑discharge policy across all sites
• Use of renewable electricity for 80% of operations
• Participation in EU green chemistry certification programs

8️⃣ Toronto Research Chemicals (Canada)

Headquarters: Toronto, Canada
Key Offering: Technical‑grade (R)-2‑Bromobutanoic acid for research laboratories

Toronto Research Chemicals supplies high‑quality chiral intermediates to academia and industrial R&D labs, emphasizing consistency and reliability. The company’s lean production model keeps inventory costs low while maintaining strict purity standards.

Sustainability Initiatives:

• Implementation of closed‑loop water recycling
• Reduction of hazardous waste by 45% through process optimization
• Collaboration with Canadian universities on green chemistry curricula

9️⃣ Hebei Guanlang Biotechnology Co., Ltd. (China)

Headquarters: Shijiazhuang, China
Key Offering: High‑purity (R)-2‑Bromobutanoic acid for agrochemical synthesis

Hebei Guanlang’s focus on agrochemical applications has led to the development of robust, scalable resolution processes that meet the strict safety and environmental regulations of the agricultural sector.

Sustainability Initiatives:

• Use of bio‑based feedstocks for bromination steps
• Implementation of real‑time emission monitoring systems
• Community engagement programs promoting sustainable farming practices

🔟 Thermo Fisher Scientific (USA)

Headquarters: Waltham, Massachusetts, USA
Key Offering: Commercial supply of pharmaceutical‑grade (R)-2‑Bromobutanoic acid and related chiral reagents

Thermo Fisher’s extensive distribution network and robust quality assurance protocols make it a reliable source for high‑purity chiral intermediates. The company’s investment in automated synthesis platforms supports rapid production of custom batches.

Sustainability Initiatives:

• Targeted reduction of solvent usage across all facilities
• Investment in renewable energy projects in North America and Europe
• Transparency in carbon footprint reporting for all product lines

---

Download FREE Sample Report: (R)-2-Bromobutanoic acid (CAS 2033-94-9) Market – View in Detailed Research Report

Get Full Report: (R)-2-Bromobutanoic acid (CAS 2033-94-9) Market – View in Detailed Research Report

---

OUTLOOK

In the next decade, the (R)-2‑Bromobutanoic acid market is expected to evolve as pharmaceutical companies continue to prioritize single‑enantiomer drugs. The convergence of advanced asymmetric catalysis, biocatalytic resolutions, and digital process monitoring will sharpen the competitive edge of suppliers that can deliver consistent, high‑purity intermediates at scale. Market participants that invest in flexible, modular manufacturing platforms will be better positioned to respond to shifting R&D priorities and regulatory expectations.

---

FUTURE TRENDS

• Expansion of enzymatic resolution methods that reduce waste and lower production costs.
• Increased demand for chiral auxiliaries in agrochemical development, driven by regulatory pressure for stereospecific pesticides.
• Adoption of real‑time analytics and AI‑driven process control to maintain enantiomeric purity during scale‑up.
• Growth of contract manufacturing organizations offering end‑to‑end chiral synthesis solutions, enabling smaller firms to access high‑purity intermediates without building in‑house capacity.
• Shift toward renewable feedstocks for bromination steps, aligning with global decarbonisation targets.